Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. by Papadatos-Pastos, D et al.
 
 
 1 
ORIGINAL ARTICLE 
Clinical outcomes and prognostic factors of patients with advanced 
mesothelioma treated in a phase I clinical trials unit 
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, Ann 
Petruckevitch, Awais Jalil, Marta Capelan, Vasiliki Michalarea, Joao Lima, Nikolaos 
Diamantis, Jaishree Bhosle, L Rhoda Molife, Udai Banerji, Johann S de Bono, 
Sanjay Popat, Mary ER O’Brien, Timothy A Yap 
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, 
London, United Kingdom 
 
Corresponding author: 
Dr Timothy A Yap 
Lung Cancer Unit, Department of Medicine, Royal Marsden NHS Foundation Trust 
and Drug Development Unit, Division of Clinical Studies, The Institute of Cancer 
Research 
Downs Road, London SM2 5PT 
United Kingdom 
Email: timothy.yap@icr.ac.uk 
 
 
 2 
Abstract 
Background: We have previously reported a prognostic score for patients in phase I 
trials in the Drug Development Unit (DDU), treated at the Royal Marsden Hospital 
(RPS). The RPS is an objective tool used in patient selection for Phase I trials based 
on albumin, number of disease sites and LDH. Patients with mesothelioma are often 
entered to phase I trials as the disease remains localised for long periods of time. 
We have now reviewed the clinical outcomes of patients with relapsed malignant 
mesothelioma (MM) and propose a specific mesothelioma prognostic score (m-RPS) 
that can help identify patients who are most likely to benefit from early referral. 
Methods: Patients who participated in 38 phase I trials between 09/2003-10/2015 
were included in the analysis. Efficacy was assessed by response rate, median 
overall survival (OS) and progression-free survival (PFS). Univariate (UVA) and 
multivariate analysis (MVA) were carried out to develop the m-RPS. 
Results: 65 patients with advanced MM were included in this retrospective study. 
PFS was 2.5 months (95% CI 2.0-3.1 months) and OS was 8 months (95% CI 5.6-
9.8 months). Four (6%) patients had RECIST partial responses; 26 (40%) patients 
had RECIST stable disease >3 months. The m-RPS was developed comprising of 3 
different prognostic factors: a neutrophil: lymphocyte ratio (NLR) greater than 3, the 
presence of more than 2 disease sites (including lymph nodes as a single site of 
disease) and albumin levels less than 35 from the MVA. Patients each received a 
score of 1 for the presence of each factor. Patients in group A (m-RPS 0-1; n=35) 
had a median OS of 13.4 months (95% CI 8.5 - 21.6), while those in group B (m-
RPS 2-3; n=30) had a median OS of 4.0 months, (95% CI 2.9 - 7.1, p<0.0001). 56 
(86%) patients experienced G1-2 toxicities, while reversible G3-4 toxicities were 
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observed in 18 (28%) patients. Only 10 (15%) patients discontinued phase I trials 
due to toxicity. 
Conclusions: Phase I clinical trial therapies were well tolerated with early signals of 
antitumor activity in advanced MM patients. The m-RPS is a useful tool to assess 
MM patient suitability for phase I trials and should now be prospectively validated. 
 
Background 
The incidence of malignant mesothelioma (MM) is increasing, with an average of 
14,200 MM cases diagnosed globally each year before a predicted plateau in 2020 
[1]. Systemic treatment and radiotherapy aim to prolong survival and improve quality 
of life for patients presenting with advanced disease not amenable to radical therapy 
or those who have disease recurrence after surgical resection [2]. 
 
Platinum chemotherapy in combination with pemetrexed with or without 
bevacizumab is the preferred first-line treatment regimen for patients with advanced 
MM [3 4]. The overall survival with platinum-based doublet chemotherapy is 
approximately one year and patients who relapse more than 6 months after 
completion of initial chemotherapy may undergo re-challenge with a platinum-based 
regimen [3]. However, at current time, there are limited approved systemic treatment 
options for patients who relapse soon after first line therapy [5]. Single agent 
chemotherapy with vinorelbine or gemcitabine are typically used in the second or 
third line settings, but evidence supporting their effectiveness in advanced MM is 
limited to retrospective or modestly-sized non-randomised studies [6, 7]. 
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Given the uncertain benefits of post first line chemotherapy, clinical trials including 
phase I studies, should be considered for patients who remain fit (e.g. Eastern 
Cooperative Oncology Group performance status [ECOG PS] 0-1) and keen to 
receive experimental therapies. Modern advances in drug discovery have led to the 
development of novel molecularly targeted inhibitors, immunotherapies and other 
antitumor agents, which may potentially be used in rational strategies that modulate 
the underlying pathogenesis of MM. For example, preclinical studies indicate that the 
phosphatidylinositol 3-kinase (PI3K) pathway is a key signalling trunk in MM, 
suggesting that critical points along this network are rational targets for therapeutic 
intervention [8]. Similarly, focal adhesion kinase (FAK) and histone deacetylase 
(HDAC) inhibitors have demonstrated promising activity in animal models of MM 
based on robust scientific rationale [9, 10]. 
 
Phase I clinical trials administered within a specialist clinical trials unit offer patients 
the opportunity to receive novel antitumor agents as single agents or in combination 
regimens before they are advanced through the different phases of clinical trials and 
approved by regulatory agencies, a process that may take several years to complete 
(www.fda.gov). We have previously developed the Royal Marsden Hospital 
prognostic score (RPS) based on objective clinical markers, as a tool for patient 
selection for phase I trial entry [11]. Most of these patients had multiple sites of 
disease while mesothelioma remains localized for most of its natural history. 
In this study, we undertook a retrospective review of the clinical characteristics and 
treatment outcomes of all patients with advanced MM who were treated on phase I 
trials in the Drug Development Unit at the Royal Marsden Hospital, London, UK. We 
focused on the safety and efficacy of these experimental treatments to assess if they 
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are comparable alternatives to approved post-1st line chemotherapy options. We also 
sought to establish a prognostic score specifically for patients with MM to improve 
phase I trial patient selection and outcomes. 
 
Patients and Methods 
We undertook a retrospective analysis of all patients with advanced MM who were 
treated in our Phase I Drug Development Clinical Trials Unit at the Royal Marsden 
Hospital, Sutton, United Kingdom, between September 2003 and October 2015. This 
retrospective study was approved by the Royal Marsden NHS Foundation Trust 
Committee for Clinical Research. All patients had histologically confirmed MM 
reviewed by expert pathologists at The Royal Marsden or the referring local 
Institution and fulfilled the eligibility criteria of their allocated clinical trial. For patients 
who participated in more than one trial, their inclusion date for this retrospective 
study is the first day on their first trial. Patient data were obtained from the Royal 
Marsden Hospital electronic patient record system. Baseline patient clinical factors 
collected included age, gender, prior lines of treatment, best response to previous 
chemotherapy, ECOG PS, primary site, histological subtype, co-morbidities and 
smoking history. 
 
Overall survival (OS) was defined as the time between treatment initiation in the first 
trial until date of death or time of their last follow up. Progression free survival (PFS) 
was defined as the length of time from commencing treatment within a phase I trial 
until the date of progression (clinical or radiological) or death while on trial. Modified 
RECIST criteria were used for all patients with pleural mesothelioma, while RECIST 
1.1 criteria were used for patients with peritoneal mesothelioma. Radiological 
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imaging review was discussed in multi-disciplinary team meetings with a specialist 
radiologist. We sought to define a MM-specific RPS (m-RPS), by assessing baseline 
patient clinical factors in univariate (UVA) and multivariate analyses (MVA), 
respectively. In the MVA, we used a full model approach, which was constructed 
using those baseline patient clinical factors found to be significant in the univariate 
analysis. The STATA Program (Version 13.0) was used to carry out the statistical 
analysis. The Kaplan-Meier method was applied to examine PFS and OS, 
respectively. The Log-rank test was used to compare survival distributions. The cox 
proportional hazards regression model was used to estimate the hazard ratio (HR) 
for each factor; All P-values presented are two sided.  
 
Results 
Baseline characteristics 
A total of 65 patients with advanced MM treated in 38 different Phase I trials at the 
Royal Marsden Hospital Drug Development Unit between September 2003 and 
October 2015 were included in the analysis. Only one trial involved a phase Ib cohort 
expansion study. Eleven patients participated in two consecutive phase I trials and 
one patient participated in four phase I trials. Baseline characteristics are shown in 
Table 1. The median age of patients at the start of their phase I trial was 64 years 
(range: 25-78 years); Sixty-one patients had pleural MM and in 49 cases it was of 
epithelioid histologic subtype. 37 (57%) patients had at least one comorbidity, with 
the most common being hypertension (n=20, 31%), vascular disease (n=7, 11%) and 
diabetes mellitus (n=5, 8%). All patients had an ECOG PS of 0-1 at phase I trial 
study entry.  
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Prior to participating in a phase I trial, the median number of lines of treatment 
received was 2 (range: 0-6 lines); 64 patients received at least one line of platinum-
based chemotherapy; one patient elected not to receive 1st line chemotherapy. 
Twenty-five (38%) patients were rechallenged with platinum-based therapy, while 22 
(34%) patients had vinorelbine chemotherapy prior to a phase I trial. 
 
Phase I trial treatments and patient outcomes 
Nine (14%) patients received chemotherapy in combination with a phase I trial agent. 
Twenty-eight (43%) and 12 (18%) patients received a PI3K pathway targeting agent 
or a histone deacetylase (HDAC) inhibitor, respectively. Table 2 details the target 
and the class of phase I trial agents used in these clinical studies.  
 
Overall, 4 (6%) patients had confirmed RECIST partial responses (to single agent 
PI3K pathway inhibitors [n=2], aurora kinase A inhibitor [n=1] and immune 
checkpoint inhibitor [n=1]); 26 (40%) patients had RECIST stable disease >3 
months. The OS and PFS for the overall study population were 8.0 months (95% CI: 
5.6-9.8 months) and 2.5 months (95% CI: 2.0-3.1 months), respectively. Patients 
who received a PI3K pathway inhibitor had a trend toward improved OS compared to 
the rest of the patient population who received other antitumor agents (median 
survival: 12.2 vs. 7.1 months, P=0.29), although PFS was similar (median survival: 
2.8 vs. 2.5 months, P=0.93) (Figure 1). 
 
Ten (15%) patients discontinued trial treatment because of drug-associated 
toxicities, while 3 (5%) subjects stopped due to patient choice for non-drug-related 
reasons. There were no deaths attributed to the investigational agent; one patient 
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died due to a lower respiratory tract infection having been on a PI3K pathway 
inhibitor trial for 8 weeks, which was deemed not to be related to the study drug. 
Overall, phase I trial treatments were well tolerated; 56 (86%) patients experienced 
G1-2 treatment-related toxicities, while G3-4 toxicities were observed in 18 (28%) 
patients. The most common G1-2 toxicities were fatigue (n=29, 45%), nausea and 
vomiting (n=19, 29%), chest wall pain (n=16, 25%), mucositis (n=12, 18%), dyspnea 
(n=11, 17%), loss of appetite (n=10, 15%) and rash (n=9, 14%). G3-4 toxicities 
included nausea (n=4, 6%), dyspnea (n=3, 5%), fatigue (n=3, 5%), anaphylaxis (n=1, 
2%), pneumonitis (n=1, 2%), rash (n=1, 2%), hyperglycemia (n=1, 2%), chest wall 
pain (n=1, 2%), back pain (n=1, 2%), neutropenia (n=1, 2%) and thrombocytopenia 
(n=1, 2%).  
 
Univariate and multivariate analyses  
In the UVA for PFS, having a diagnosis of peritoneal MM, having two or fewer sites 
of disease, the absence of lymph nodes but not the neutrophil:lymphocyte ratio 
(NLR), were associated with improved PFS in our series of patients (Appendix, 
Table 1). The UVA for OS showed that the female gender, having a diagnosis of 
peritoneal MM, previously receiving more than 1 prior line of chemotherapy, the 
presence of two or fewer sites of disease, the absence of lymph nodes, having 
albumin levels of at least 35, and a neutrophil-lymphocyte ratio (NLR) of less than 3 
were associated with improved OS (Appendix, Table 2).  
 
Subsequently, in the MVA that was constructed using the significant univariate 
variables, the presence of lymph nodes at baseline emerged as an independent 
prognostic factor for reduced PFS (HR: 3.12, 95% CI: 1.7-5.8, P<0.001), while 
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having received more than 2 lines of treatment prior to participating in phase I trials 
was associated with prolonged PFS (HR: 0.5, 95% CI: 0.3–0.9, P=0.028) (Table 3). 
Having a NLR greater than 3, the presence of pathologically enlarged lymph nodes 
and the presence of more than 2 sites of disease at baseline were associated with 
poor overall survival (HR: 2.1, 95% CI: 1.0–4.2, P=0.048; HR: 2.3, 95% CI: 1.1-4.6, 
P=0.024; HR: 4.0, 95% CI: 1.7-9.2, P=0.001, respectively). Having serum albumin 
levels of at least 35g/L (HR: 0.3, 95% CI: 0.1-0.6, P=0.001), previously receiving 
more than 2 lines of treatment prior to a phase I trial (HR: 0.3, 95% CI: 0.2-0.6, 
P<0.001) and the best response of RECIST PR or SD to first line chemotherapy (HR: 
0.3, 95% CI: 0.1-0.8, P=0.019) were all associated with increased OS (Table 4). 
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MM-specific RMH Prognostic Score (m-RPS) 
We subsequently sought to define a m-RPS by assessing baseline patient factors 
that were found to be significantly associated with OS in the MVA (Table 5). 
Therefore, a m-RPS comprising 3 different prognostic factors was developed, 
including a NLR greater than 3, the presence of more than 2 disease sites (including 
the presence of pathologically enlarged lymph nodes as a single disease site) and 
albumin levels less than 35g/L; each receiving a m-RPS score of 1 if present. These 
factors have previously been found to be prognostic in separate studies involving 
patients participating in phase I clinical studies, but have never been considered 
together in the context of a prognostic score [11, 12]. All three factors assessed 
objective data at treatment baseline and reflect the disease state of the individual 
patient.  
 
We elected not to include ‘response to first line chemotherapy’ in our prognostic 
model since cancers may accumulate genomic and epigenetic events that alter the 
genomic composition of the original tumor that dictated its initial response to 
chemotherapy. Similarly, the number of prior lines of chemotherapy received by 
patients is subjective and is dependent on the preferences of the patient and 
referring oncologist. The ‘number of disease sites’ was selected as a factor for the 
m-RPS rather than the ‘presence of pathologically enlarged lymph nodes’ because it 
was a statistically stronger prognostic factor in the MVA. Unlike the original RPS, 
LDH was not significant in the MVA. 
 
Accordingly, by applying this m-RPS to our patient population, patients were divided 
into two groups; group A: those with a good prognosis (n=35, m-RPS 0-1) and group 
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B: those with a poor prognosis (n=30, m-RPS 2-3). The median OS was 13.4 months 
(95% CI: 8.5-21.6) for group A, and 4.0 months (95% CI 2.9-7.1) in group B, 
P<0.0001 (Figure 2). No patients in group A died within 90 days from the start of the 
trial, whereas the 90-day mortality rate was 33% (10/30 patients) in group B. This is 
an important factor since a life expectancy > 90 days is a common inclusion criteria 
for phase I trials. Of note, 5 of 6 patients with an m-RPS of 3 died within 90 days of 
treatment initiation, supporting the prognostic value of the m-RPS in patients with 
advanced MM referred for phase I trial consideration. 
 
Discussion 
The main objectives of a phase I clinical trial are the assessment of safety and 
tolerability, as well as the establishment of a recommended phase 2 dose schedule 
for the future development of novel anticancer agents [13, 14]. Patients with relapsed 
MM gain limited therapeutic benefit from conventional treatment options after first 
line platinum-based chemotherapy and may therefore, be considered for phase I 
trials if fit [5-7]. The OS of 8.0 months and the PFS of 2.5 months described in this 
retrospective series are comparable to the survival data reported in published 
studies describing the use of single agent chemotherapy in relapsed MM (OS range 
4.9–9.6 months; PFS 1.6-1.7 months suggesting that phase I trials are a reasonable 
alternative to second line chemotherapy [5-7]. 
 
Importantly, these phase I trial agents were well tolerated, with mainly G1-2 toxicities 
observed, such as fatigue, nausea and mucositis. The frequency of G3-4 adverse 
events of 28% was comparable with previously reported data from larger datasets of 
patients with solid tumors participating in phase I studies and were importantly fully 
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reversible upon dose interruption or discontinuation [15, 16]. Of note, Raphael and 
colleagues described a higher rate of G3-4 toxicity, possibly because patients with 
ECOG PS2 were included in their analysis; A performance status of ECOG PS2 has 
previously been identified to be predictive for the onset of G3 or worse toxicity [16, 
17]. There was no drug-related death in our series of patients which did not include 
PS 2, which is consistent with the low mortality rate (∼0.5%) reported in other 
analyses of mortality in phase I oncology programmes [13, 14, 17]. 
 
Although 26 (40%) patients in our study had a best response of RECIST SD lasting 
greater than 3 months, it is possible that this was confounded by slowly progressing 
MM in these patients. In our study, patients were not ‘molecularly matched’ to 
targeted therapies and not unexpectedly, only a modest number of patients gained 
clinical benefit. In future, patient selection will be central to improving the number of 
patients that benefit from molecularly targeted agents in phase I trials. For example, 
the increased use of next-generation sequencing (NGS) technologies in the clinic 
has enhanced our understanding of changes that occur at a molecular level and may 
aid in the matching of advanced MM patients with novel therapeutics to optimise 
benefit from Phase I trial therapies [8].  
 
Anecdotal examples of RECIST partial responses were observed in patients treated 
in our series of patients with novel PI3K pathway (n=2), aurora kinase (n=1) and 
immune checkpoint inhibitors (n=1). None of these classes of drugs would have 
been available to these patients outside these early phase clinical trials. These 
preliminary antitumor responses thus support the referral of such patients for 
consideration of novel agents given within the context of phase I clinical trials in 
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dedicated drug development units, and demonstrates the utility of these studies for 
preliminary antitumor efficacy signal searching in different tumor types including 
mesothelioma. 
 
While the molecular characterisation of patients may contribute to the selection of 
patients more likely to benefit from a phase I trial, it does not aid in the prognostic 
determination of patient mortality within the first 3 months of trial treatment. Such a 
predicted life expectancy of 3 months is a key inclusion criteria of phase I clinical 
trials, but is challenging to predict. Since its validation in a prospective study, the 
RPS has been incorporated in the selection process of patients with advanced solid 
tumors for phase I trials [11]. An important limitation of the RPS is that given the 
pattern of disease spread in advanced MM, it cannot be reliably applied to this group 
of patients. Our MM-specific m-RPS was developed from baseline factors that 
significantly correlated with OS in a MVA. Patients with a m-RPS of 0-1 are suitable 
candidates for phase I trials as there were no deaths recorded in this group within 90 
days of study initiation. This is in contrast to patients with an m-RPS of 2-3 who had 
a 90-day mortality rate of 33%. Furthermore, 5 of 6 patients with an m-RPS of 3 died 
within 90 days of treatment initiation, thus representing a patient population with very 
poor life expectancy with limited chances of benefit from a phase I trial. This scoring 
system now needs to be prospectively validated to serve as a clinical tool to aid in 
the selection of patients with MM referred for participation on phase I clinical trials. It 
may also be possible that the m-RPS could be of use as a prognostic tool in other 
treatment settings in advanced MM, for example in second or third line MM clinical 
trials, where an estimated prognosis of more than 3 months is often a mandatory 
entry criterion. 
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Patients with relapsed MM have limited treatment options and based on our data and 
other studies, phase I trials represent bona fide options, which are associated with 
potential clinical benefit and acceptable toxicities [17]. Since the identification of 
molecular pathways implicated in the oncogenesis of MM and the development of 
novel therapies that target such critical targets, the process of allocating patients to 
suitable trials is likely to become increasingly biology-driven. A MM-specific, 
validated prognostic tool, such as the m-RPS developed in this study, will also aid in 
the optimal selection of patients with advanced MM for participation in phase I 
clinical trials, and minimise the inclusion of individuals who are unlikely to remain on 
study for a sufficient duration of time to derive any potential meaningful benefit. 
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Table 1. Baseline characteristics 
Median age 64 years (range 25-78 years) 
Gender 
 
Male: 43 
Female: 22 
Median lines of treatment pre phase I 2 (range 1-6) 
Best response to first line 
chemotherapy 
 
PR: 22 
SD: 35 
PD: 7 
NA: 1 
Number of patients that had platinum 
re-challenge  
25 
Number of patients that had vinorelbine  22 
Mean PFS after first line chemotherapy 8.1 months 
Lines of treatment with a phase I trial 
 
1: 53 
2: 11 
4: 1 
ECOG PS 
 
PS 0: 5 
PS 1: 60 
Primary site  
 
Pleura: 61 
Peritoneal: 4 
Histological type 
 
Epithelioid: 49 
Biphasic: 4 
Sarcomatoid: 2 
Unknown: 10 
Number of co-morbidities 
 
≤2: 56 
>2: 9 
Type of co-morbidities 
 
Hypertension: 20 
Vascular: 7 
Diabetes mellitus: 5 
Smoking history: Yes: 6 
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 Ex-smoker: 18 
No: 16  
Unknown: 25 
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Table 2. List of phase I studies classified by target class and target 
 
Target class Target Number of 
patients 
Cytoplasmic signalling protein PI3K pathway  28 
IGF  4 
VEGF  1 
Pan-HER family 1 
AGC kinase  1 
 
DNA repair and Antisense HDAC 12 
PARP 4 
ATR 4 
Aurora A  3 
 
Cytotoxic Microtubule  1 
Alpha folate receptor 1 
Nucleoside analogue 2 
 
Other Oleic acid analogue 1 
Immune checkpoints 4 
Apoptosis 2 
MCT-1 1 
Chemotherapy 
combination 
9 
PI3K: Phosphoinositide 3-kinase; IGF: Insulin-like growth factor 1; VEGF: 
Vascular endothelial growth factor; HER: human epidermal growth factor 
receptor; AGC: protein kinase A, G, and C families; HDAC: Histone 
deacetylase; PARP: Poly ADP ribose polymerase; ATR: ataxia 
telangiectasia and Rad3-related protein; MCT-1: Monocarboxylate 
transporter 1 
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Table 3: Multiple regression analysis – multivariate analysis for PFS 
 
Variable HR 95% CI for HR Cox PH test 
Lymph nodes -
Yes 3.12 1.70 – 5.75 0.000 
What line of 
treatment phase 
1 - >2 0.53 0.30 – 0.93 0.028 
Constructed using significant univariate models (n=62) 
Progression free survival (p<0.05) 
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Table 4: Multiple regression analysis – multivariate analysis for OS 
 
Variable 
HR 
95% CI for 
HR Cox PH test 
NL ratio - >3 2.06 1.01 – 4.23 0.048 
Lymph Nodes  - Yes 2.26 1.11 – 4.61 0.024 
Number of metastatic sites > 2 3.97 1.71 – 9.20 0.001 
Albumin≥35 0.29 0.14 – 0.59 0.001 
>2 prior lines of treatment 0.30 0.15 – 0.59 0.000 
Best response to first line chemo – 
PR & SD 0.29 0.11 – 0.82 0.019 
Overall survival (P<0.005) 
Constructed using significant univariate models (n=61) 
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Table 5. RPS and m-RPS 
 
RPS m-RPS 
Variable score Variable score 
Low albumin (<35 g/dL) +1 Low albumin (<35 g/dL) +1 
Elevated LDH (>1XULN) +1 NLR > 3 +1 
Number of metastatic 
sites > 2 
+1 Number of sites of 
disease >2 
+1 
 
Categories score Categories score 
Good prognosis 0-1 Good prognosis 0-1 
Poor prognosis 2-3 Poor prognosis 2-3 
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Figure 1. Overall survival in patients treated on a PI3K inhibitor-based trial 
versus patients treated with a non-PI3K inhibitor based trial 
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Figure 2. Overall survival in group A (progcat 1) and group B (progcat 2) 
 
 
 
 
